CMG Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
CMG Pharmaceutical makes medicines and health-supplement products, with a core focus on a thin, fast-dissolving oral film, a strip placed on the tongue that delivers a drug without water, using its proprietary STARFILM Technology.
Its products reach patients and consumers through pharmaceutical and health-care channels. Listed on KOSDAQ, Korea's tech and small-cap board, the company is expanding its product portfolio beyond its current medicines into oncology, anti-aging, eye care, health supplements, and mother-and-baby categories, while also pursuing new and improved-formulation drug development.
Summary is AI-generated and may contain errors · figures from DART filings
CMG Pharmaceutical is described in its filing as a core affiliate of the Cha Bio Group, a Korean life-sciences conglomerate.
CMG Pharmaceutical in five facts
What does CMG Pharmaceutical do?
CMG Pharmaceutical makes medicines and health-supplement products, with a core focus on a thin, fast-dissolving oral film, a strip placed on the tongue that delivers a drug without water, using its proprietary STARFILM Technology.
Where is CMG Pharmaceutical listed and in which sector?
CMG Pharmaceutical (Korean name: CMG제약) trades under KRX code 058820 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is CMG Pharmaceutical?
Its market capitalisation was US$62.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were CMG Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, CMG Pharmaceutical reported revenue of US$79.4M, an operating loss of US$2.8M and a net loss of US$7.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 6.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Oct 14
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Oct 12
- Report on securities held by executives/major shareholdersOct 12
- Report on large shareholdings (5% rule) (standard)Oct 12
- Report on securities held by executives/major shareholdersOct 12
- Trading suspension (share consolidation/split registration)M&A · Sep 28
- Results of extraordinary shareholders' meetingSep 2
- Early redemption of convertible bonds (incl. overseas CBs)
CMG Pharmaceutical Co., Ltd. redeemed US$13.9M face value of its Series 8 public convertible bonds (issued July 11, 2024, conversion price US$1.19) before maturity on July 13, 2026 for US$14.3M following a bondholder put-option request, funded from convertible-bond issuance proceeds, leaving US$15M outstanding.
Capital raise · Jul 13 - Material event report (convertible bonds)
CMG Pharmaceutical disclosed convertible bonds to raise US$29.1M, about 54.1% of its market value.
Capital raise · Jun 30 - Supply contract terminatedSupply contract · Jun 19
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
CMG Pharmaceutical reported consolidated results for FY2025: revenue of US$72.3M (+6.2% year on year), an operating loss of US$2.54M (from a profit a year earlier) and a net loss of US$6.16M (from a profit a year earlier).
Earnings · Feb 11